AI-generated analysis. Always verify with the original filing.
Compass Pathways plc announced the successful achievement of the primary endpoint in the Phase 3 COMP006 trial, the second of two Phase 3 trials evaluating COMP360 for treatment-resistant depression, with highly statistically significant reduction in MADRS scores at Week 6 for 25 mg versus 1 mg doses. The company plans to meet with the FDA to discuss a rolling NDA submission expected in Q4.
Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section
Other Events. On February 17, 2026, the Company announced the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of
. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Investor Presentation dated February 17, 2026. 104 Cover page interactive data f